Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17818578 | 0.92 | KLKB1 (1.00) | KLKB1KLK1 | |
| SCHEMBL17818642 | 0.91 | KLKB1 (1.00) | KLKB1KLK1 | |
| SCHEMBL17818600 | 0.88 | KLKB1 (1.00) | KLKB1KLK1 | |
| SCHEMBL16486700 | 0.88 | KLKB1 (1.00) | KLKB1KLK1 | |
| SCHEMBL20198530 | 0.87 | KLKB1 (0.85) | KLKB1KLK1 | |
| SCHEMBL17818576 | 0.87 | KLKB1 (1.00) | KLKB1KLK1 | |
| SCHEMBL17818616 | 0.86 | KLKB1 (1.00) | KLKB1KLK1 | |
| SCHEMBL17818574 | 0.86 | KLKB1 (1.00) | KLKB1KLK1 | |
| SCHEMBL17818631 | 0.85 | KLKB1 (1.00) | KLKB1KLK1 | |
| SCHEMBL17818629 | 0.85 | KLKB1 (1.00) | KLKB1KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153724-A1 | Inhibitors Of Plasma Kallikrein | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-05-19 | — | — | US | disclosed |
| US-11242333-B2 | Inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-02-08 | — | — | US | disclosed |
| US-20190152950-A1 | Inhibitors Of Plasma Kallikrein | KALVISTA PHARMACEUTICALS LTD (GB) | 2019-05-23 | — | — | US | disclosed |
| US-10221161-B2 | Inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2019-03-05 | — | — | US | disclosed |
| EP-3033336-B1 | INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2018-05-30 | — | — | EP | disclosed |
| US-20160168123-A1 | INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152950-A1 | Inhibitors Of Plasma Kallikrein | KLKB1, SERPINB1, KLK5 | KLKB1 1/4885KLK1 4/4885 |
| US-20220153724-A1 | Inhibitors Of Plasma Kallikrein | KLKB1, SERPINB1, KLK5 | KLKB1 1/4885KLK1 4/4885 |
| US-11242333-B2 | Inhibitors of plasma kallikrein | KLKB1, SERPINB1, KLK5 | KLKB1 1/4885KLK1 4/4885 |
| US-10221161-B2 | Inhibitors of plasma kallikrein | KLKB1, SERPINB1, KLK5 | KLKB1 1/4885KLK1 4/4885 |
| US-20160168123-A1 | INHIBITORS OF PLASMA KALLIKREIN | KLKB1, SERPINB1, KLK5 | KLKB1 1/4885KLK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.